Skip to content
← All treatment topics

TREATMENT READING

Pheochromocytoma and Paraganglioma

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

52 sections
  1. Treatment Option Overview for Pheochromocytoma and Paraganglioma
  2. Localized and Regional Pheochromocytoma
  3. Metastatic Pheochromocytoma
  4. Preoperative Medical Preparation
  5. Treatment of Localized Pheochromocytoma
  6. Treatment Options for Localized Pheochromocytoma
  7. Surgery
  8. Treatment Options for Inherited Pheochromocytoma
  9. Surgery
  10. Treatment of Regional Pheochromocytoma
  11. Treatment Options for Regional Pheochromocytoma
  12. Surgery
  13. Treatment of Metastatic Pheochromocytoma
  14. Treatment Options for Metastatic Pheochromocytoma
  15. Surgery
  16. Palliative therapy
  17. Chemotherapy
  18. Targeted therapy
  19. Radiation therapy
  20. Other therapy
  21. Treatment of Recurrent Pheochromocytoma
  22. Treatment Options for Recurrent Pheochromocytoma
  23. Surgery
  24. Palliative therapy
  25. Treatment Options for Inherited Pheochromocytoma or Paraganglioma
  26. Treatment of Pheochromocytoma During Pregnancy
  27. Diagnosis
  28. Treatment Options for Pheochromocytoma During Pregnancy
  29. Genetic counseling is part of the treatment plan for patients with pheochromocytoma or paraganglioma.
  30. Certain factors affect prognosis (chance of recovery) and treatment options.
  31. Pheochromocytoma and paraganglioma can recur (come back) after they have been treated.
  32. Treatment Option Overview
  33. Key Points
  34. There are different types of treatment for patients with pheochromocytoma or paraganglioma.
  35. Patients receive medication to treat the signs and symptoms of pheochromocytoma and paraganglioma.
  36. The following types of treatment are used:
  37. Surgery
  38. Radiation therapy
  39. Chemotherapy
  40. Ablation therapy
  41. Embolization therapy
  42. Targeted therapy
  43. New types of treatment are being tested in clinical trials.
  44. Treatment for pheochromocytoma and paraganglioma may cause side effects.
  45. Follow-up care will be needed.
  46. Treatment of Pheochromocytoma and Paraganglioma
  47. Localized Pheochromocytoma and Paraganglioma
  48. Inherited Pheochromocytoma
  49. Regional Pheochromocytoma and Paraganglioma
  50. Metastatic Pheochromocytoma and Paraganglioma
  51. Recurrent Pheochromocytoma and Paraganglioma
  52. Treatment of pregnant women with pheochromocytoma may include surgery.

Health professional

Treatment Option Overview for Pheochromocytoma and Paraganglioma

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 1, 2024. Captured 2026-09-09.

Limited data are available from phase II clinical trials to guide the management of patients diagnosed with pheochromocytoma or paraganglioma. There are no phase III trials. Everything is based on case series, and the impact on survival is not known.

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional · Treatment Option Overview for Pheochromocytoma and Paraganglioma

Localized and Regional Pheochromocytoma

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 1, 2024. Captured 2026-09-09.

Definitive treatment for localized and regional pheochromocytoma, including localized disease recurrence, consists of alpha- and beta-adrenergic blockade followed by surgery.

Health professional · Treatment Option Overview for Pheochromocytoma and Paraganglioma

Metastatic Pheochromocytoma

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 1, 2024. Captured 2026-09-09.

For patients with unresectable or metastatic pheochromocytoma, treatment may include a combination of:

Catecholamine blockade.

Surgery.

Chemotherapy.

Radiofrequency ablation.

Cryoablation.

Radiation therapy.

Treatment for patients with localized, regional, metastatic, or recurrent pheochromocytoma is summarized in Table 2.

Sources: Table 2

Table 2. Treatment Options for Patients With Pheochromocytoma
Clinical StageTreatment Options
Localized pheochromocytomaSurgery
Regional pheochromocytomaSurgery
Metastatic pheochromocytomaSurgery
Palliative therapy
Recurrent pheochromocytomaSurgery
Palliative therapy

Sources: Surgery · Surgery · Surgery · Palliative therapy · Surgery · Palliative therapy

Health professional · Treatment Option Overview for Pheochromocytoma and Paraganglioma

Preoperative Medical Preparation

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 1, 2024. Captured 2026-09-09.

Surgery is the mainstay of treatment for most patients; however, preoperative medical preparation is critical. Alpha-adrenergic blockade should be initiated at the time of diagnosis and maximized preoperatively to prevent potentially life-threatening cardiovascular complications, which can occur as a result of excess catecholamine secretion during surgery. Complications may include:

Hypertensive crisis.

Arrhythmia.

Myocardial infarction.

Pulmonary edema.

Phenoxybenzamine (a nonselective alpha-antagonist) is the usual drug of choice; prazosin, terazosin, and doxazosin (selective alpha-1-antagonists) are alternative choices.[1,2] Prazosin, terazosin, and doxazosin are shorter acting than phenoxybenzamine, and therefore, the duration of postoperative hypotension is theoretically less than with phenoxybenzamine; however, there is less overall experience with selective alpha-1-antagonists than with phenoxybenzamine.

Sources: 1 · 2

A preoperative treatment period of 1 to 3 weeks is usually sufficient; resolution of spells and a target low normal blood pressure for age indicate that alpha-adrenergic blockade is adequate. During alpha-adrenergic blockade, liberal salt and fluid intake should be encouraged because volume loading reduces excessive orthostatic hypotension both preoperatively and postoperatively. If tachycardia develops or if blood pressure control is not optimal with alpha-adrenergic blockade, a beta-adrenergic blocker (e.g., metoprolol or propranolol) can be added, but only after alpha-blockade. Beta-adrenergic blockade must never be initiated before alpha-adrenergic blockade; doing so blocks beta-adrenergic receptor-mediated vasodilation and results in unopposed alpha-adrenergic receptor-mediated vasoconstriction, which can lead to a life-threatening crisis.

Health professional

Treatment of Localized Pheochromocytoma

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 1, 2024. Captured 2026-09-09.

Health professional · Treatment of Localized Pheochromocytoma

Treatment Options for Localized Pheochromocytoma

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 1, 2024. Captured 2026-09-09.

Treatment options for localized pheochromocytoma include:

Surgery.

Sources: Surgery

Health professional · Treatment of Localized Pheochromocytoma / Treatment Options for Localized Pheochromocytoma

Surgery

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 1, 2024. Captured 2026-09-09.

Surgical resection (i.e., adrenalectomy) is the definitive treatment for patients with localized pheochromocytoma. A minimally invasive adrenalectomy is generally the preferred approach if the following conditions can be met:

Preoperative imaging reveals an adrenal pheochromocytoma that is approximately 6 cm or smaller in diameter.

No radiographic evidence of invasion into adjacent structures or evidence of regional or metastatic disease (i.e., presumably a benign tumor).

Normal contralateral adrenal gland.

Both anterior transabdominal laparoscopic adrenalectomy and posterior retroperitoneoscopic adrenalectomy have been demonstrated to be safe for most patients with a modestly sized, radiographically benign pheochromocytoma.[1,2] If preoperative imaging suggests malignancy, or if the patient has an extra-adrenal paraganglioma or multifocal disease, an open approach is generally preferred.

Sources: 1 · 2

Intraoperative hypertension can be controlled with intravenous infusion of phentolamine, sodium nitroprusside, or a short-acting calcium-channel blocker (e.g., nicardipine). Tumor removal may be followed by a sudden drop in blood pressure that may require rapid volume replacement and intravenous vasoconstrictors (e.g., norepinephrine or phenylephrine). Postoperatively, patients should remain in a monitored environment for 24 hours. Postoperative hypotension is managed primarily by volume expansion, and postoperative hypertension usually responds to diuretics.

Health professional · Treatment of Localized Pheochromocytoma

Treatment Options for Inherited Pheochromocytoma

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 1, 2024. Captured 2026-09-09.

Treatment options for inherited pheochromocytoma include:

Surgery.

Sources: Surgery

Health professional · Treatment of Localized Pheochromocytoma / Treatment Options for Inherited Pheochromocytoma

Surgery

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 1, 2024. Captured 2026-09-09.

The surgical management of pheochromocytoma in patients with the hereditary syndromes multiple endocrine neoplasia type 2 (MEN2) or von Hippel-Lindau (VHL) disease has been controversial. In both of these syndromes, pheochromocytoma is bilateral in at least 50% of patients; however, malignancy is very uncommon. Bilateral total adrenalectomy commits all patients to lifelong steroid dependence, and up to 25% of patients will experience Addisonian crisis (acute adrenal insufficiency).[3,4]

Sources: 3 · 4

Recommendations generally favor preservation of adrenal cortical tissue in patients with MEN2 or VHL when possible. Patients who initially present with unilateral pheochromocytoma should undergo unilateral adrenalectomy, and patients who present with bilateral pheochromocytomas or who develop pheochromocytoma in their remaining adrenal gland should undergo cortical-sparing adrenalectomy, when technically feasible.[3]

Sources: 3

Evidence (surgery):

A single-institution study included 56 patients with adrenal pheochromocytomas.[5]

Sources: 5

A single-institution study included 56 patients with adrenal pheochromocytomas.[5]

Of the 30 patients who underwent one or more cortical-sparing adrenalectomies, 17 (57%) avoided the need for routine steroid replacement.

The clinical recurrence rate was low (3 of 30 patients) and none of the patients developed metastatic disease.[5][Level of evidence C2]

Sources: 5 · Level of evidence C2

A similar approach may be reasonable in other hereditary pheochromocytoma-paraganglioma syndromes that are characterized by benign disease, but there are insufficient data upon which to base unequivocal recommendations. For more information, see Genetics of Endocrine and Neuroendocrine Neoplasias.

Sources: Genetics of Endocrine and Neuroendocrine Neoplasias

Health professional

Treatment of Regional Pheochromocytoma

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 1, 2024. Captured 2026-09-09.

Health professional · Treatment of Regional Pheochromocytoma

Treatment Options for Regional Pheochromocytoma

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 1, 2024. Captured 2026-09-09.

Treatment options for regional pheochromocytoma include:

Surgery.

Sources: Surgery

Health professional · Treatment of Regional Pheochromocytoma / Treatment Options for Regional Pheochromocytoma

Surgery

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 1, 2024. Captured 2026-09-09.

Surgical resection is the definitive treatment for pheochromocytoma or extra-adrenal paraganglioma that is regionally advanced (e.g., from direct tumor extension into adjacent organs or because of regional lymph node involvement). Data to guide management are limited because regional disease is diagnosed in very few patients who present with pheochromocytoma.[1] However, aggressive surgical resection to remove all existing disease can render patients symptom free.[2] Surgical management of these patients may require en bloc resection of all or part of adjacent organs (e.g., kidney, liver, inferior vena cava) along with extended lymph node dissection. Patients who have undergone complete resection of regional pheochromocytoma require lifelong monitoring for disease recurrence.

Sources: 1 · 2

Health professional

Treatment of Metastatic Pheochromocytoma

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 1, 2024. Captured 2026-09-09.

Health professional · Treatment of Metastatic Pheochromocytoma

Treatment Options for Metastatic Pheochromocytoma

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 1, 2024. Captured 2026-09-09.

Treatment options for metastatic pheochromocytoma include:

Surgery.

Sources: Surgery

Palliative therapy.

Sources: Palliative therapy

The most common sites of metastasis for pheochromocytoma or extra-adrenal paraganglioma are lymph nodes, bones, lungs, and liver. Patients with known or suspected malignancy should undergo staging with computed tomography or magnetic resonance imaging as well as functional imaging (e.g., with iodine I 123-metaiodobenzylguanidine [MIBG]) to determine the extent and location of disease. Patients are often very symptomatic from excess catecholamine secretion. Phenoxybenzamine is effective, and metyrosine, which is a drug that blocks catecholamine synthesis, can be added if needed.

Health professional · Treatment of Metastatic Pheochromocytoma / Treatment Options for Metastatic Pheochromocytoma

Surgery

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 1, 2024. Captured 2026-09-09.

If all identifiable disease is resectable, including a limited number of distant metastases, surgery can provide occasional long-term remission. If disease is unresectable, surgical debulking will not improve survival; however, it is occasionally indicated for symptom palliation.

Health professional · Treatment of Metastatic Pheochromocytoma / Treatment Options for Metastatic Pheochromocytoma

Palliative therapy

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 1, 2024. Captured 2026-09-09.

Health professional · Treatment of Metastatic Pheochromocytoma / Treatment Options for Metastatic Pheochromocytoma / Palliative therapy

Chemotherapy

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 1, 2024. Captured 2026-09-09.

Chemotherapy has not been shown to improve survival in patients with metastatic pheochromocytoma; however, chemotherapy may be useful for symptom palliation.

The best-established chemotherapy regimen is a combination of cyclophosphamide, vincristine, and dacarbazine (the Averbuch protocol).[1]

Sources: 1

Evidence (chemotherapy):

A nonrandomized single-arm trial included 18 patients with metastatic malignant pheochromocytoma or paraganglioma. Patients were treated with a combination of cyclophosphamide, vincristine, and dacarbazine.[2]

Sources: 2

A nonrandomized single-arm trial included 18 patients with metastatic malignant pheochromocytoma or paraganglioma. Patients were treated with a combination of cyclophosphamide, vincristine, and dacarbazine.[2]

After 22 years of follow-up, the complete response rate was 11%, the partial response rate was 44%, the biochemical response rate was 72%, and the median survival was 3.3 years.[2][Level of evidence C3]

Sources: 2 · Level of evidence C3

A retrospective study showed a therapeutic benefit of temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Fifteen consecutive patients with metastatic pheochromocytoma or paraganglioma were enrolled; 10 (67%) had an SDHB variant. The mean dose intensity of temozolomide was 172 mg/m2 daily for 5 days every 28 days.[3]

Sources: 3

A retrospective study showed a therapeutic benefit of temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Fifteen consecutive patients with metastatic pheochromocytoma or paraganglioma were enrolled; 10 (67%) had an SDHB variant. The mean dose intensity of temozolomide was 172 mg/m2 daily for 5 days every 28 days.[3]

The median progression-free survival was 13.3 months after a median follow-up of 35 months. Of the 15 patients, 5 (33%) had a partial response, 7 (47%) had stable disease, and 3 (20%) had progressive disease.[3][Level of evidence C3]

Sources: 3 · Level of evidence C3

Several other chemotherapy regimens have been used in small numbers of patients, but the overall results were disappointing.[4,5]

Sources: 4 · 5

Health professional · Treatment of Metastatic Pheochromocytoma / Treatment Options for Metastatic Pheochromocytoma / Palliative therapy

Targeted therapy

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 1, 2024. Captured 2026-09-09.

Novel targeted therapies are emerging as potential treatment strategies for metastatic pheochromocytoma. Disappointing initial results were reported with the mammalian target of rapamycin (mTOR) inhibitor everolimus,[6] but results from a very small number of patients treated with the tyrosine kinase inhibitors sunitinib, axitinib, and cabozantinib have been more promising.[7,8][Level of evidence C3]

Sources: 6 · 7 · 8 · Level of evidence C3

Health professional · Treatment of Metastatic Pheochromocytoma / Treatment Options for Metastatic Pheochromocytoma / Palliative therapy

Radiation therapy

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 1, 2024. Captured 2026-09-09.

Iodine I 131 (131I)-MIBG radiation therapy has been used for the treatment of patients with MIBG-avid metastases.[9,10] Approximately 60% of metastatic pheochromocytoma or paraganglioma sites are MIBG-avid;[11] protocol-based treatment with other experimental radiolabeled agents, such as radiolabeled somatostatin, can be considered for metastases that do not take up MIBG.

Sources: 9 · 10 · 11

Evidence (radiation therapy):

A phase II study of high-dose 131I-MIBG radiation therapy included 49 patients with metastatic pheochromocytoma or paraganglioma.[11] Iobenguane I 131 is a high-specific-activity 131I-MIBG agent made of labeled MIBG molecules that allows lower mass doses of MIBG to be given for adult and pediatric patients (age >12 years) with advanced unresectable disease. It has been shown to be safe and generally well tolerated and was approved by the U.S. Food and Drug Administration via fast track designation in 2018.

Sources: 11

A phase II study of high-dose 131I-MIBG radiation therapy included 49 patients with metastatic pheochromocytoma or paraganglioma.[11] Iobenguane I 131 is a high-specific-activity 131I-MIBG agent made of labeled MIBG molecules that allows lower mass doses of MIBG to be given for adult and pediatric patients (age >12 years) with advanced unresectable disease. It has been shown to be safe and generally well tolerated and was approved by the U.S. Food and Drug Administration via fast track designation in 2018.

Eight percent of patients had a complete response, 14% had a partial response, and the estimated 5-year survival rate was 64%.[11][Level of evidence C3]

Sources: 11 · Level of evidence C3

A phase II, open-label, multicenter trial included 68 patients with pheochromocytoma or paraganglioma. The primary end point was a greater than 50% reduction of all antihypertensive medications lasting for at least 6 months.[12][Level of evidence C3]

Sources: 12 · Level of evidence C3

A phase II, open-label, multicenter trial included 68 patients with pheochromocytoma or paraganglioma. The primary end point was a greater than 50% reduction of all antihypertensive medications lasting for at least 6 months.[12][Level of evidence C3]

Twenty-five percent of evaluable patients experienced a 50% or greater reduction of all antihypertensive medication for at least 6 months.

Overall tumor response was achieved in 22% of patients and, of those patients, 53% experienced durable tumor responses lasting 6 months or longer.

Health professional · Treatment of Metastatic Pheochromocytoma / Treatment Options for Metastatic Pheochromocytoma / Palliative therapy

Other therapy

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 1, 2024. Captured 2026-09-09.

Other palliative treatment modalities include external-beam radiation therapy (e.g., for palliation of bone metastases) and embolization, radiofrequency ablation, or cryoablation (e.g., for palliation of bulky hepatic metastases or isolated bony metastases).

Pheochromocytoma and paraganglioma often express the somatostatin receptor proteins SSTR2 and SSTR3 which may allow for targeted treatment with somatostatin receptor agonists.[13,14] A meta-analysis of studies involving advanced or metastatic pheochromocytoma and paraganglioma patients treated with peptide receptor radionuclide therapy showed that 89.8% of pooled patients had achieved disease stabilization or a partial response.[15][Level of evidence C3]

Sources: 13 · 14 · 15 · Level of evidence C3

Health professional

Treatment of Recurrent Pheochromocytoma

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 1, 2024. Captured 2026-09-09.

Health professional · Treatment of Recurrent Pheochromocytoma

Treatment Options for Recurrent Pheochromocytoma

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 1, 2024. Captured 2026-09-09.

Treatment options for recurrent pheochromocytoma include:

Surgery.

Sources: Surgery

Palliative therapy.

Sources: Palliative therapy

After resection of a localized pheochromocytoma presumed to represent a benign tumor and documented normal postoperative biochemical testing, disease recurrence occurs in 6.5% to 16.5% of patients, and 50% of patients with disease recurrence develop metastatic disease.[1-3] Insufficient data exist to determine recurrence rates after complete surgical resection of regional or metastatic disease.

Sources: 1 · 3

Health professional · Treatment of Recurrent Pheochromocytoma / Treatment Options for Recurrent Pheochromocytoma

Surgery

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 1, 2024. Captured 2026-09-09.

Treatment for recurrent disease involves appropriate medical management (i.e., alpha-adrenergic blockade) followed by complete surgical resection, when possible.

Health professional · Treatment of Recurrent Pheochromocytoma / Treatment Options for Recurrent Pheochromocytoma

Palliative therapy

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 1, 2024. Captured 2026-09-09.

Palliation of symptoms, including those related to catecholamine excess and local mass effect, is the primary focus of treatment for disease that is not resectable.

Options for patients with local-regional or metastatic disease who are not considered candidates for surgical resection include:

Chemotherapy.

Targeted therapies.

High-dose iodine I 131-metaiodobenzylguanidine radiation therapy.

Ablation therapies.

Radiation therapy.

For more information, see the Treatment of Metastatic Pheochromocytoma section.

Sources: Treatment of Metastatic Pheochromocytoma

Health professional · Treatment of Recurrent Pheochromocytoma

Treatment Options for Inherited Pheochromocytoma or Paraganglioma

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 1, 2024. Captured 2026-09-09.

Patients with inherited pheochromocytoma or paraganglioma are at risk of recurrent disease in the form of additional primary tumors. Follow-up evaluation and management of additional primary tumors in such patients is essential. For more information, see the Treatment of Localized Pheochromocytoma section.

Sources: Treatment of Localized Pheochromocytoma

Health professional

Treatment of Pheochromocytoma During Pregnancy

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 1, 2024. Captured 2026-09-09.

Pheochromocytoma diagnosed during pregnancy is extremely rare (0.007% of all pregnancies).[1,2] However, women with hereditary conditions that increase the risk of developing pheochromocytoma are often also of childbearing age, and the outcome of undiagnosed pheochromocytoma during pregnancy can be catastrophic.

Sources: 1 · 2

Health professional · Treatment of Pheochromocytoma During Pregnancy

Diagnosis

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 1, 2024. Captured 2026-09-09.

Prenatal diagnosis clearly results in decreased mortality for both mother and fetus.[3] Prior to 1970, a prenatal diagnosis of pheochromocytoma was made in only approximately 25% of cases, and the mortality rate for both mother and fetus was around 50%.[4,5] The prenatal diagnosis rate rose to greater than 80% through the 1980s and 1990s, and decreased maternal and fetal mortality rates were 6% and 15%, respectively.[4,6]

Sources: 3 · 4 · 5 · 4 · 6

The diagnosis of pheochromocytoma should be suspected in any pregnant woman who develops hypertension in the first trimester, paroxysmal hypertension, or hypertension that is unusually difficult to treat.[2,7] Normal pregnancy does not affect catecholamine levels.[8] Thus, the usual biochemical tests are valid. Magnetic resonance imaging is the localization method of choice because it does not expose the fetus to ionizing radiation.

Sources: 2 · 7 · 8

Health professional · Treatment of Pheochromocytoma During Pregnancy

Treatment Options for Pheochromocytoma During Pregnancy

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 1, 2024. Captured 2026-09-09.

Phenoxybenzamine use is safe in pregnancy, but beta-adrenergic blockers should be initiated only if needed because their use has been associated with intrauterine growth restriction.[9,10] Resection of the tumor can often be performed safely during the second trimester, or tumor resection can be combined with cesarean delivery for patients diagnosed later in pregnancy.[2] Case reports have documented successful outcomes in the rare circumstance when surgical resection was delayed until a short time after vaginal delivery.[11] The successful management of pheochromocytoma in pregnancy depends on careful monitoring and the availability of an experienced team of specialists.

Sources: 9 · 10 · 2 · 11

For patients · General Information About Pheochromocytoma and Paraganglioma

Genetic counseling is part of the treatment plan for patients with pheochromocytoma or paraganglioma.

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 10, 2025. Captured 2026-09-09.

All patients who are diagnosed with pheochromocytoma or paraganglioma should have genetic counseling to find out their risk for having an inherited syndrome and other related cancers.

Sources: diagnosed · genetic counseling

Genetic testing is often recommended by a genetic counselor for patients who:

Sources: Genetic testing

Have a personal or family history of traits linked with inherited pheochromocytoma or paraganglioma syndrome.

Sources: family history

Have tumors in both adrenal glands.

Have more than one tumor in one adrenal gland.

Have signs or symptoms of extra catecholamines being released into the blood or malignant (cancerous) paraganglioma.

Are diagnosed before age 40 years.

Genetic testing is sometimes recommended for patients with pheochromocytoma who:

Are aged 40 to 50 years.

Have a tumor in one adrenal gland.

Do not have a personal or family history of an inherited syndrome.

When certain gene changes are found during genetic testing, the testing is usually offered to family members who are at risk but do not have signs or symptoms.

Genetic testing is not recommended for patients older than 50 years.

For patients · General Information About Pheochromocytoma and Paraganglioma

Certain factors affect prognosis (chance of recovery) and treatment options.

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 10, 2025. Captured 2026-09-09.

The prognosis and treatment options depend on:

Sources: prognosis

Whether the tumor is benign or malignant.

Sources: malignant

Whether the tumor is in one area only or has spread to other places in the body.

Whether there are signs or symptoms caused by a higher-than-normal amount of catecholamines.

Whether the tumor has just been diagnosed or has recurred (come back).

Sources: recurred

For patients · Stages of Pheochromocytoma and Paraganglioma / Pheochromocytoma and paraganglioma are described as localized, regional, or metastatic.

Pheochromocytoma and paraganglioma can recur (come back) after they have been treated.

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 10, 2025. Captured 2026-09-09.

The cancer may come back in the same place or in other parts of the body.

For patients

Treatment Option Overview

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 10, 2025. Captured 2026-09-09.

For patients · Treatment Option Overview

Key Points

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 10, 2025. Captured 2026-09-09.

There are different types of treatment for patients with pheochromocytoma or paraganglioma.

Patients receive medication to treat the signs and symptoms of pheochromocytoma and paraganglioma.

The following types of treatment are used:

The following types of treatment are used:

Surgery

Radiation therapy

Chemotherapy

Ablation therapy

Embolization therapy

Targeted therapy

New types of treatment are being tested in clinical trials.

Treatment for pheochromocytoma and paraganglioma may cause side effects.

Follow-up care will be needed.

For patients · Treatment Option Overview

There are different types of treatment for patients with pheochromocytoma or paraganglioma.

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 10, 2025. Captured 2026-09-09.

Different types of treatments are available for patients with pheochromocytoma or paraganglioma. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment

Sources: pheochromocytoma · paraganglioma · standard · clinical trials · research study

For patients · Treatment Option Overview

Patients receive medication to treat the signs and symptoms of pheochromocytoma and paraganglioma.

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 10, 2025. Captured 2026-09-09.

Drug therapy begins when pheochromocytoma or paraganglioma is diagnosed. This may include:

Drugs that keep the blood pressure normal. For example, one type of drug called alpha-blockers stops noradrenaline from making small blood vessels more narrow. Keeping the blood vessels open and relaxed improves blood flow and lowers blood pressure.

Sources: blood pressure · alpha-blockers · noradrenaline · blood vessels

Drugs that keep the heart rate normal. For example, one type of drug called beta-blockers stops the effect of too much noradrenaline and slows the heart rate.

Drugs that block the effect of extra hormones made by the adrenal gland.

Sources: hormones · adrenal gland

Drug therapy is often given for one to three weeks before surgery.

For patients · Treatment Option Overview

The following types of treatment are used:

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 10, 2025. Captured 2026-09-09.

For patients · Treatment Option Overview / The following types of treatment are used:

Surgery

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 10, 2025. Captured 2026-09-09.

Surgery to remove pheochromocytoma is usually an adrenalectomy (removal of one or both adrenal glands). During this surgery, the tissues and lymph nodes inside the abdomen will be checked and if the tumor has spread, these tissues may also be removed. Drugs may be given before, during, and after surgery to keep blood pressure and heart rate normal.

Sources: adrenalectomy · lymph nodes · abdomen

After surgery to remove the tumor, catecholamine levels in the blood or urine are checked. Normal catecholamine levels are a sign that all the pheochromocytoma cells were removed.

Sources: catecholamine · sign

If both adrenal glands are removed, life-long hormone therapy to replace hormones made by the adrenal glands is needed.

Sources: hormone therapy

For patients · Treatment Option Overview / The following types of treatment are used:

Radiation therapy

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 10, 2025. Captured 2026-09-09.

Radiation therapy uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing.

Sources: Radiation therapy · x-rays · radiation

External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer.

Sources: External radiation therapy

Metastatic pheochromocytoma is sometimes treated with a radioactive substance called 131I-MIBG. It is given by infusion to deliver radiation directly to tumor cells throughout the body. 131I-MIBG collects in certain kinds of tumor cells, killing them with the radiation that is given off. Not all pheochromocytomas take up 131I-MIBG, so a test is done first to check for this before treatment begins.

Sources: infusion

The way the radiation therapy is given depends on whether the cancer is localized, regional, metastatic, or recurrent. External radiation therapy and 131I-MIBG therapy are used to treat pheochromocytoma.

Sources: localized · regional · metastatic · recurrent · 131I-MIBG

For patients · Treatment Option Overview / The following types of treatment are used:

Chemotherapy

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 10, 2025. Captured 2026-09-09.

Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy). Combination chemotherapy is treatment using more than one anticancer drug. Systemic chemotherapy is used to treat pheochromocytomas and paragangliomas.

Sources: Chemotherapy · injected · systemic chemotherapy

For patients · Treatment Option Overview / The following types of treatment are used:

Ablation therapy

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 10, 2025. Captured 2026-09-09.

Ablation is a treatment to remove or destroy a body part or tissue or its function. Ablation therapies used to help kill cancer cells include:

Sources: Ablation

Radiofrequency ablation: A procedure that uses radio waves to heat and destroy abnormal cells. The radio waves travel through electrodes (small devices that carry electricity). Radiofrequency ablation may be used to treat cancer and other conditions.

Sources: Radiofrequency ablation · abnormal · electrodes

Cryoablation: A procedure in which tissue is frozen to destroy abnormal cells. Liquid nitrogen or liquid carbon dioxide is used to freeze the tissue.

Sources: Cryoablation · carbon dioxide

For patients · Treatment Option Overview / The following types of treatment are used:

Embolization therapy

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 10, 2025. Captured 2026-09-09.

Embolization therapy is a treatment to block the artery leading to the adrenal gland. Blocking the flow of blood to the adrenal glands helps kill cancer cells growing there.

Sources: Embolization · artery

For patients · Treatment Option Overview / The following types of treatment are used:

Targeted therapy

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 10, 2025. Captured 2026-09-09.

Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells. Tyrosine kinase inhibitors (TKIs) block signals needed for tumors to grow. Sunitinib, axitinib, and cabozantinib have been used as palliative therapy for metastatic and recurrent pheochromocytoma.

Sources: Targeted therapy · Tyrosine kinase inhibitors · Sunitinib · axitinib · cabozantinib · palliative therapy

For patients · Treatment Option Overview

New types of treatment are being tested in clinical trials.

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 10, 2025. Captured 2026-09-09.

For some people, joining a clinical trial may be an option. There are different types of clinical trials for people with cancer. For example, a treatment trial tests new treatments or new ways of using current treatments. Supportive care and palliative care trials look at ways to improve quality of life, especially for those who have side effects from cancer and its treatment.

You can use the clinical trial search to find NCI-supported cancer clinical trials accepting participants. The search allows you to filter trials based on the type of cancer, your age, and where the trials are being done. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.

Sources: clinical trial search · ClinicalTrials.gov

Learn more about clinical trials, including how to find and join one, at Clinical Trials Information for Patients and Caregivers.

Sources: Clinical Trials Information for Patients and Caregivers

For patients · Treatment Option Overview

Treatment for pheochromocytoma and paraganglioma may cause side effects.

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 10, 2025. Captured 2026-09-09.

For information about side effects caused by treatment for cancer, visit our Side Effects page.

Sources: side effects · Side Effects

For patients · Treatment Option Overview

Follow-up care will be needed.

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 10, 2025. Captured 2026-09-09.

Some of the tests that were done to diagnose the cancer or to find out the extent of the cancer may be repeated. Some tests will be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment will be based on the results of these tests.

Some of the tests will continue to be done after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back). These tests are sometimes called follow-up tests.

Sources: recurred

For patients with pheochromocytoma or paraganglioma that causes symptoms, catecholamine levels in the blood and urine will be checked on a regular basis. Catecholamine levels that are higher than normal can be a sign that the cancer has come back.

Sources: symptoms

For patients with paraganglioma that does not cause symptoms, follow-up tests, such as CT, MRI, or MIBG scan should be done every year.

Sources: CT · MRI · MIBG

For patients with inherited pheochromocytoma or paraganglioma, catecholamine levels in the blood and urine will be checked on a regular basis. Other screening tests will be done to check for other tumors that are linked to the inherited syndrome.

Sources: inherited · screening · syndrome

Talk to your doctor about which tests should be done and how often. Patients with pheochromocytoma or paraganglioma need lifelong follow-up.

For patients

Treatment of Pheochromocytoma and Paraganglioma

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 10, 2025. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

For patients · Treatment of Pheochromocytoma and Paraganglioma

Localized Pheochromocytoma and Paraganglioma

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 10, 2025. Captured 2026-09-09.

Treatment of localized benign pheochromocytoma or paraganglioma is usually surgery to completely remove the tumor. If the tumor is in the adrenal gland, the entire adrenal gland is removed.

Sources: localized · benign · pheochromocytoma · paraganglioma · adrenal gland

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients · Treatment of Pheochromocytoma and Paraganglioma

Inherited Pheochromocytoma

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 10, 2025. Captured 2026-09-09.

In patients with inherited pheochromocytoma linked to multiple endocrine neoplasia (MEN2) or von Hippel-Lindau (VHL) syndrome, tumors often form in both adrenal glands. The tumors are usually benign.

Sources: inherited · pheochromocytoma · multiple endocrine neoplasia · von Hippel-Lindau (VHL) syndrome · adrenal glands · benign

Treatment for inherited pheochromocytoma that forms in one adrenal gland is surgery to completely remove the gland.

Treatment for inherited pheochromocytoma that forms in both adrenal glands or later forms in the remaining adrenal gland may be surgery to remove the tumor and as little normal tissue in the adrenal cortex as possible.

Sources: adrenal cortex

These surgeries may help patients avoid life-long hormone replacement therapy, acute adrenal insufficiency, and health problems due to the loss of hormones made by the adrenal gland.

Sources: hormone replacement therapy · acute · adrenal insufficiency · hormones

For patients · Treatment of Pheochromocytoma and Paraganglioma

Regional Pheochromocytoma and Paraganglioma

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 10, 2025. Captured 2026-09-09.

Treatment of pheochromocytoma or paraganglioma that has spread to nearby organs or lymph nodes is surgery to completely remove the tumor. Nearby organs that the cancer has spread to, such as the kidney, liver, part of a major blood vessel, and lymph nodes, may also be removed.

Sources: pheochromocytoma · paraganglioma · lymph nodes · kidney · liver · blood vessel

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients · Treatment of Pheochromocytoma and Paraganglioma

Metastatic Pheochromocytoma and Paraganglioma

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 10, 2025. Captured 2026-09-09.

Treatment of metastatic pheochromocytoma or paraganglioma may include:

Sources: metastatic · pheochromocytoma · paraganglioma

Surgery to completely remove the cancer, including tumors that have spread to distant parts of the body.

Palliative therapy, to relieve symptoms and improve the quality of life, including:

Sources: Palliative therapy · symptoms · quality of life

Palliative therapy, to relieve symptoms and improve the quality of life, including:

Surgery to remove as much cancer as possible.

Combination chemotherapy.

Sources: Combination chemotherapy

Radiation therapy with 131I-MIBG.

Sources: Radiation therapy · 131I-MIBG

External radiation therapy to areas (such as bone) where cancer has spread and cannot be removed by surgery.

Sources: External radiation therapy

Embolization (treatment to block an artery that supplies blood to a tumor).

Sources: Embolization · artery

Ablation therapy using radiofrequency ablation or cryoablation for tumors in the liver or bone.

Sources: Ablation · radiofrequency ablation · cryoablation · liver

Targeted therapy (tyrosine kinase inhibitors).

Sources: Targeted therapy · tyrosine kinase inhibitors

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients · Treatment of Pheochromocytoma and Paraganglioma

Recurrent Pheochromocytoma and Paraganglioma

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 10, 2025. Captured 2026-09-09.

Treatment of recurrent pheochromocytoma or paraganglioma may include:

Sources: recurrent · pheochromocytoma · paraganglioma

Surgery to completely remove the cancer.

When surgery to remove the cancer is not possible, palliative therapy to relieve symptoms and improve the quality of life may include:

Sources: palliative therapy · symptoms · quality of life

When surgery to remove the cancer is not possible, palliative therapy to relieve symptoms and improve the quality of life may include:

Combination chemotherapy.

Sources: Combination chemotherapy

Targeted therapy.

Sources: Targeted therapy

Radiation therapy using 131I-MIBG.

Sources: Radiation therapy · 131I-MIBG

External radiation therapy to areas (such as bone) where cancer has spread and cannot be removed by surgery.

Sources: External radiation therapy

Ablation therapy using radiofrequency ablation or cryoablation.

Sources: Ablation · radiofrequency · cryoablation

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients · Pheochromocytoma During Pregnancy

Treatment of pregnant women with pheochromocytoma may include surgery.

Source: Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 10, 2025. Captured 2026-09-09.

Treatment of pheochromocytoma during pregnancy may include:

Surgery to completely remove the cancer during the second trimester (the fourth through the sixth month of pregnancy).

Surgery to completely remove the cancer combined with delivery of the baby by cesarean section for patients diagnosed later in pregnancy.

Studies

Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs

NCT04711135 · ACTIVE NOT RECRUITING · phase2

Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma

ClinicalTrials.gov record

Drug labels

AdreView

Label date 2024-01-10

AdreView is a radiopharmaceutical agent for gamma-scintigraphy indicated for: use in the detection of primary or metastatic pheochromocytoma or neuroblastoma as an adjunct to other diagnostic tests ( 1.1 ) scintigraphic assessment of...

DailyMed label

Demser

Label date 2021-07-01

INDICATIONS AND USAGE DEMSER is indicated in the treatment of patients with pheochromocytoma for: 1. Preoperative preparation of patients for surgery 2. Management of patients when surgery is contraindicated 3. Chronic treatment of...

DailyMed label

Metyrosine

Label date 2021-07-01

INDICATIONS AND USAGE Metyrosine is indicated in the treatment of patients with pheochromocytoma for: 1. Preoperative preparation of patients for surgery 2. Management of patients when surgery is contraindicated 3. Chronic treatment of...

DailyMed label